Literature DB >> 12730682

cDNA microarray analysis of genes associated with ERBB2 (HER2/neu) overexpression in human mammary luminal epithelial cells.

Alan Mackay1, Chris Jones, Tim Dexter, Ricardo L A Silva, Karen Bulmer, Allison Jones, Peter Simpson, Robert A Harris, Parmjit S Jat, A Munro Neville, Luiz F L Reis, Sunil R Lakhani, Michael J O'Hare.   

Abstract

To investigate changes in gene expression associated with ERBB2, expression profiling of immortalized human mammary luminal epithelial cells and variants expressing a moderate and high level of ERBB2 has been carried out using cDNA microarrays corresponding to approximately 6000 unique genes/ESTs. A total of 61 significantly up- or downregulated (2.0-fold) genes were identified and further validated by RT-PCR analysis as well as microarray comparisons with a spontaneously ERBB2- overexpressing breast cancer cell line and ERBB2-positive primary breast tumors. The expression and clinical relevance of proteins predicted to be associated with ERBB2 overexpression in breast cancers were analysed together with their clinical relevance by antibody screening using a tissue array. Differentially regulated genes include those involved in cell-matrix interactions including proline 4-hydroxylase (P4HA2), galectin 1 (LGALS1) and galectin 3 (LGALS3), fibronectin 1 (FN1) and p-cadherin (CDH3), and cell proliferation (CRIP1, IGFBP3) and transformation (S100P, S100A4). A number of genes associated with MYC signalling were also differentially expressed, including NDRG1, USF2 and the epithelial membrane proteins 1 and 3 (EMP1, EMP3). These data represent profiles of the transcriptional changes associated with ERBB2-related pathways in the breast, and identify novel and potentially useful targets for prognosis and therapy.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12730682     DOI: 10.1038/sj.onc.1206349

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  47 in total

Review 1.  Using gene expression arrays to elucidate transcriptional profiles underlying prolactin function.

Authors:  Sandra Gass; Jessica Harris; Chris Ormandy; Cathrin Brisken
Journal:  J Mammary Gland Biol Neoplasia       Date:  2003-07       Impact factor: 2.673

Review 2.  S100P: a novel therapeutic target for cancer.

Authors:  Thiruvengadam Arumugam; Craig D Logsdon
Journal:  Amino Acids       Date:  2010-05-28       Impact factor: 3.520

3.  Proteomic profiling identifies breast tumor metastasis-associated factors in an isogenic model.

Authors:  Paweena Kreunin; Chul Yoo; Virginia Urquidi; David M Lubman; Steve Goodison
Journal:  Proteomics       Date:  2007-01       Impact factor: 3.984

4.  Insights into gene expression changes impacting B-cell transformation: cross-species microarray analysis of bovine leukemia virus tax-responsive genes in ovine B cells.

Authors:  Pavel Klener; Maud Szynal; Yvette Cleuter; Makram Merimi; Hugues Duvillier; Françoise Lallemand; Claude Bagnis; Philip Griebel; Christos Sotiriou; Arsène Burny; Philippe Martiat; Anne Van den Broeke
Journal:  J Virol       Date:  2006-02       Impact factor: 5.103

5.  MicroRNA target detection and analysis for genes related to breast cancer using MDLcompress.

Authors:  Scott C Evans; Antonis Kourtidis; T Stephen Markham; Jonathan Miller; Douglas S Conklin; Andrew S Torres
Journal:  EURASIP J Bioinform Syst Biol       Date:  2007

Review 6.  Review of the GAS3 Family of Proteins and their Relevance to Cancer.

Authors:  Negin Ashki; Lynn Gordon; Madhuri Wadehra
Journal:  Crit Rev Oncog       Date:  2015

7.  Gene expression analysis of immune-mediated arrest of tumorigenesis in a transgenic mouse model of HER-2/neu-positive basal-like mammary carcinoma.

Authors:  Annalisa Astolfi; Lorena Landuzzi; Giordano Nicoletti; Carla De Giovanni; Stefania Croci; Arianna Palladini; Silvano Ferrini; Manuela Iezzi; Piero Musiani; Federica Cavallo; Guido Forni; Patrizia Nanni; Pier-Luigi Lollini
Journal:  Am J Pathol       Date:  2005-04       Impact factor: 4.307

8.  Trastuzumab and lapatinib modulation of HER2 tyrosine/threonine phosphorylation and cell signaling.

Authors:  D Kostyal; R S Welt; J Danko; T Shay; C Lanning; K Horton; S Welt
Journal:  Med Oncol       Date:  2011-07-16       Impact factor: 3.064

9.  The oncogene HER2/neu (ERBB2) requires the hypoxia-inducible factor HIF-1 for mammary tumor growth and anoikis resistance.

Authors:  Kelly A Whelan; Luciana P Schwab; Sergey V Karakashev; Lisa Franchetti; Gregg J Johannes; Tiffany N Seagroves; Mauricio J Reginato
Journal:  J Biol Chem       Date:  2013-04-12       Impact factor: 5.157

10.  Genomic signatures of breast cancer metastasis.

Authors:  V Urquidi; S Goodison
Journal:  Cytogenet Genome Res       Date:  2007       Impact factor: 1.636

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.